Status:
COMPLETED
A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Conditions:
Peritoneal Dialysis
Hyperphosphatemia
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.
Eligibility Criteria
Inclusion
- Receiving stable maintenance peritoneal dialysis
- Peritoneal dialysis patients with hyperphosphatemia
Exclusion
- Patients having history of a pronounced brain / cardiovascular disorder
- Patients having severe gastrointestinal disorders
- Patients having severe hepatic disorders
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01852682
Last Update
November 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tokyo and Other Japanese City, Japan